Search

Search Results

• Book

  Cancer genetics : a clinical approach

  editors, Xavier Llor, Erin Wysing Hofstatter.

  Summary: "A guide and comprehensive reference for the care of patients with hereditary cancer syndromes. This book is intended to provide the essential tools needed to understand clinical cancer genetics"-- Provided by publisher.
  
  Contents:
  Critical Cancer Genetics
  Risk Assessment In The Primary Care Office : Identification Of Patients For Referral
  Principals Of Cancer Risk Assessment And Genetic Counseling
  Laboratory Methods In Cancer Genetics Testing
  Breast Cancer
  Gastrointestinal Polyposis Syndromes
  Hereditary Non-Polyposis Colorectal Cancers
  Risk Assessment And Clinical Management-- Uterine Cancer
  Risk Assessment And Clinical Management-- Ovarian Cancer
  Pancreatic Cancer Genetics
  Risk Assessment and Clinical Management-- Genito-Urinary Tract Cancer
  Genetic Predisposition To Gastric Cancer
  Endocrine Cancers
  Risk Assessment And Clinical Management-- Skin Cancer
  Risk Assessment And Clinical Management-- Pediatric And Other Cancers
  Ethical, Legal And Psychosocial Issues In Cancer Genetic Assessment And Genetic Test
  Talking To Children And Family About Hereditary Cancer Risk And Genetic Test Results
  Future Challenges And Opportunities In Clinical Cancer Genomics.

  Digital Access AccessHemOnc 2022
  Get Shareable Link

  View Details
• Journal

  The Imprint.

  Digital Access Full text via HathiTrust, v. 1-2 (no. 1-9) ; Jan.-Nov. 1913.
  Get Shareable Link

  View Details
• Article

  A double-blind trial of mazindol using a very low calorie formula diet.

  Baird IM, Howard AN.

  Int J Obes. 1977;1(3):271-8.

  Thirty-eight obese patients, resistant to conventional diet therapy, agreed to consume a 1.09 MJ (260 kcal)/day semi-synthetic diet consisting of 25 g egg albumin, 40 g oligosaccharides, vitamins and minerals, and were seen weekly as outpatients for eight weeks. At the beginning, the semi-synthetic diet was given with either the anorectic drug, mazindol (2 mg/day) or a placebo for four weeks and then changed over for the remaining four weeks; the study being conducted on a double-blind basis. The final treatment was a 4.2 MJ (1000 KCAL) conventional diet for a further four weeks without drug or placebo. Twenty-five patients completed the first eight weeks and 21 patients the final four weeks of the trial. The total mean weight losses were as follows: week 4, 9.3 kg; week 8, 13.7 kg; week 12, 12.2 kg. There was no significant difference in weight loss between mazindol treatment and placebo but the former group reported feeling less hungry. The chief side-effects observed were dizziness, nausea, dry mouth, insomnia and depression which were more frequent with mazindol. Six patients had to stop mazindol because of side-effects, but were able to continue the diet alone. It is concluded that a semi-synthetic diet containing 1.09 MJ (260 kcal) daily can be successfully employed in the treatment of obese outpatients, and is a practical therapeutic alternative to admission to hospital. There is no clinical advantage to be gained by the additional use of the anorectic drug, mazindol.

  Digital Access Access Options
  Get Shareable Link

  PubMed